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ABSTRACT 
Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in the Western 
world and is caused by an abnormal accumulation of B lymphocytes in peripheral blood, 
bone marrow and lymphoid organs. It is a disease mainly of adults. 
The clinical outcome of CLL may differ significantly. Some patients have an indolent 
leukemia with long survival, while others experience an aggressive disease, with an acute 
need for treatment. At present, no treatment regimen can be considered curative. Novel 
therapeutic approaches are required. Those aimed at directing the body’s natural defense 
system against the tumor cells require well characterized targets that are exclusively 
expressed by the tumor cells. 
In 2001, microarray studies revealed FMOD, a member of the Small Leucine Rich 
Proteoglycan family (SLRP) and ROR1, a member of the Receptor Tyrosine Kinase 
(RTK) family, as two genes being overexpressed in CLL compared to healthy controls. 
SLRPs are normally expressed and secreted into the extracellular matrix of collagen-rich 
tissues. They interact with collagen and participate in signaling regulation by the interaction 
with integrins, growth factors and their receptors. RTKs are transmembrane receptors for 
growth factors, cytokines and hormones and play important roles in cellular processes 
including proliferation, differentiation, migration, metabolism and survival.  
The ectopic expression of FMOD and ROR1 in CLL was unexpected and was the 
prelude to this thesis. FMOD is located on chromosome 1 adjacent to two other members 
of the SLRP family; PRELP and OPTC.  
In this project, we investigated FMOD, PRELP, OPTC and ROR1 at the gene as well 
as protein levels and their expression in CLL compared to healthy individuals and other 
hematological malignancies. We also investigated the effect of siRNA silencing of FMOD 
and ROR1 in CLL and normal control cells. 
FMOD, PRELP, OPTC and ROR1 were expressed in all CLL patients but not in 
normal controls. ROR1 was detected on the surface of CLL cells, which corresponds to the 
natural ROR1 localization. PRELP and OPTC, on the other hand, seemed to be abnormally 
retained within the CLL cells, rather than secreted. The PRELP and OPTC proteins 
expressed in CLL were further investigated and found to be differentially glycosylated 
compared to their normal counterparts. The molecular weight of the detected PRELP and 
OPTC corresponded to completely unglycosylated core proteins. PRELP was detected in 
the cytosol of CLL cells, while CLL OPTC was found in the nucleus and endoplasmic 
reticulum.  
Using siRNA technology, FMOD and ROR1 were efficiently downregulated which 
resulted in apoptosis of CLL cells but not of B cells from healthy donors. This suggests that 
FMOD and ROR1 may be important for the survival of CLL cells.  
In conclusion, four genes, FMOD, PRELP, OPTC and ROR1, were found to be 
ectopically expressed by CLL cells. At least two of these genes, FMOD and ROR1, may be 
important for CLL cell survival. The reason for the aberrant expressions is not yet known, 
but once elucidated it may contribute to the understanding of the pathogenesis of CLL. 
Also, these novel markers might be suitable targets for future immunotherapy in CLL.
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In this thesis, the gene and protein symbols for FMOD, PRELP, OPTC and ROR1 are 
all printed in non-italicized form for the sake of simplicity. For other genes and 
proteins, the designations are usually those used in the sited articles. 
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1 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 
1.1 CLINICAL FEATURES OF CLL 
CLL is the most common form of leukemia in the Western world, representing about 25-
30% of all leukemias.[1] It is characterized by the abnormal accumulation of functionally 
incompetent B lymphocytes in peripheral blood (PB), bone marrow (BM), lymph nodes 
(LN) and spleen.[2] CLL is a disease of the elderly and the incidence increases with age. 
The median age at diagnosis is around 72 years.[3] The worldwide incidence is between 
<1 and 5.5 per 100.000 people and year.[4] The disease is more common in men than in 
women and in addition, the disease is more frequent in the European population 
compared to the African or Asian.[1, 5, 6] The etiology of CLL is still unknown but higher 
prevalence of the disease in relatives of CLL patients suggests a genetic role.[7-10] There is 
so far no association with either environmental factors or viral infections.[2, 11] 
CLL is a heterogeneous disease with a highly variable clinical course, mainly falling 
into two subclasses; indolent or progressive. Indolent CLL may have a stable or a very 
slowly increasing peripheral lymphocyte count. It may not develop into a severe 
condition for many years, and patients can survive long periods without treatment. 
Progressive CLL, however, is characterized by a more aggressive disease with rapid 
doubling-time of the tumor cells, and can be fatal in a short period of time.[12, 13] 
Although between 0,1% and 1,75% of CLL cells are actively dividing every day[14], 
the majority of cells are arrested in the G0 phase of the cell cycle.[15] Compared to normal 
B cells that have a life span of only a few days, circulating CLL cells can survive for 
several months.[13] The accumulation of CLL cells is due to an imbalance between birth 
and death rates such that the former exceeds the latter.[14] 
With the help of improved diagnostic tools, 70–80% of the CLL cases are discovered 
in an early indolent phase.[16] There has also been a major progression in understanding 
the pathogenesis of the disease but despite new treatment regimens leading to improved 
overall survival, CLL is still considered an incurable disease.[17] There is a constant need 
for more knowledge and improved treatment strategies. 
1.1.1 Diagnosis of CLL 
CLL is often discovered by chance, when increased lymphocyte counts are found during 
routine check-ups.[18] However, some patients are diagnosed upon symptoms and classic 
first signs of CLL are fatigue, anemia and mild enlargement of LN, liver and spleen. As 
the disease progresses, the patients often experience fever, weight loss and night sweats. 
When the disease becomes more advanced, severe anemia, thrombocytopenia and 
neutropenia are seen due to BM infiltration by tumor cells.[11,12,18] As signs and symptoms 
develop gradually, it may be difficult to pinpoint the actual onset of the disease. 
The diagnosis of CLL is based on the presence of more than 5.0x109/L  
B lymphocytes in blood. Immunophenotypic analysis is also required and CLL cells are 
CD19+, CD5+, CD20+, CD23+, FMC7- with weak expression of surface immunoglobulin 
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(sIg) and weak/neg expression of membrane CD79b. The leukemic cells are monoclonal, 
with light chain restriction (kappa or lambda Ig light chain).[12] 
1.1.2 Prognosis of CLL 
CLL is a disease with a highly variable course, with survival ranging from months to 
several years. Some patients, with very indolent disease, may not require therapy, but for 
patients with a more aggressive disease, the need for treatment may be urgent. Therefore, 
the prediction of disease course and selection of suitable treatment regimens are of great 
importance and the number of prognostic factors is steadily increasing.  
1.1.2.1 Clinical prognostic factors 
Rai (stage 0-IV)[19] and Binet (stage A-C)[20] staging systems (Table 1), both reflecting 
tumor burden, have been used for many years and are still the cornerstone in predicting 
the course of the disease.[3] The systems divide patients into prognostic groups predicting 
median survival. Patients with Rai stage 0 and Binet stage A disease belong to the low-
risk group with a median survival of more than 10 years. Rai stage I + II and Binet stage 
B are classified as intermediate-risk with a median survival of 6-8 years. Rai stage III + 
IV and Binet stage C indicate high-risk patients with a median survival of less than 4 
years. The drawback of these systems is that they fail to identify patients, who are 
diagnosed in an early stage and will face a rapid progression.[21]  
 
Table 1. Rai classification and Binet staging systems for CLL (adapted from Gribben, 2010)[3]  
System Clinicalfeatures Mediansurvival,
year
Raistage(simplified3Ͳstage)  
 0(lowrisk) Lymphocytosisinbloodandbonemarrow >10
 IandII(intermediaterisk) Lymphadenopathy,splenomegaly
+/Ͳhepatomegaly
7
 IIIandIV(highrisk) Anemia,thrombocytopenia 0.75–4
Binetgroup  
 A Fewerthan3areasoflymphadenopathy;no
anemiaorthrombocytopenia
12
 B Morethan3involvednodeareas;noanemia
orthrombocytopenia
7
 C Hemoglobin<100g/L,platelets<100x10g/L 2Ͳ4
 
 
Another traditional prognostic parameter is lymphocyte doubling time (LDT). The 
definition of LDT is “the number of months in which the lymphocytes double in 
number”.[22] A low LDT (<12 months) indicates an aggressive course and short survival.  
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1.1.2.2 Serum markers 
Lactate dehydrogenase 
Lactate dehydrogenase (LDH) is an enzyme present in most organisms. Serum LDH level 
is considered a marker of cell turnover and increased LDH levels in CLL are associated 
with shorter survival.[21, 23] LDH may, however, also be increased due to autoimmune 
hemolytic anemia,[24] a not uncommon complication in CLL. 
 
Thymidine kinase 
Thymidine kinase (TK) is an enzyme found in most living cells. It plays an important 
role in DNA synthesis (and thereby in cell division), being part of the unique reaction 
chain to introduce deoxythymidine into the growing DNA strand. The predominant 
cytosolic form of TK is a useful marker of proliferation, since it is present in dividing 
cells but not in non-dividing cells. In CLL, high serum TK levels have been associated 
with progressive disease and bad prognosis.[12, 25] 
 
ȕ2-microglobulin 
E2-microglobulin (E2-M) is a membrane protein associated with the D-chain of the MHC 
class I molecule. Normally, E2-M is present in small amounts in serum but the increased 
production or destruction of E2-M bearing cells causes E2-M levels in the blood to 
increase. In CLL, high serum levels of E2-M correlate with advanced stage and poor 
prognosis.[26] 
 
Soluble CD23 
CD23 is a membrane glycoprotein which may be cleaved into soluble fragments 
(sCD23). Functions of the soluble CD23 are among others (1) prevention of germinal 
center B cells from their entry into apoptosis[27] and (2) proliferation of myeloid precursor 
cells.[28] In CLL sera, sCD23 is elevated (3–500-fold) compared to control sera and 
provokes the CLL cells to enter the S phase of the cell cycle.[29] The levels of sCD23 in 
CLL correlate with disease activity as well as prognosis.[30-32]  
1.1.2.3 Cytogenetic and molecular markers 
Chromosomal aberrations 
Several chromosomal abnormalities are reported in CLL and can be detected in up to 
80% of the cases using fluorescence in situ hybridization (FISH). The most common 
alterations are 13q14 deletion, 11q22-q23 deletion, trisomy 12, 17p13 deletion and 6q21 
deletion.[33] There is an important correlation between these aberrations and prognosis. 
Deletion of 13q14 is associated with a better prognosis, while 17p13 del and 11q22-q23 
del are associated with worse prognosis.[33, 34] Cytogenetic changes at 17p13, which lead 
to loss of p53 function, is clinically the most important factor to consider, as it affects 
choice of therapy. Conventional therapy is not effective in cases with p53 mutations/ 
deletion.[35-37]  
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IgVH mutational status 
In 1999, the correlation between IgVH (Ig variable region of the heavy chain) mutational 
status and prognosis was established and turned the diagnosis of CLL into a new path.[38, 
39] During normal B cell development, B cells undergo a number of events to achieve 
binding specificity for the surface Igs. The initial steps (VDJ gene rearrangements, class 
switching and nucleotide ins/del) are followed by the introduction of point mutations 
(somatic hypermutations). 50-70% of the CLL patients have mutated IgVH genes ( 2% 
difference from the germline sequence)[40, 41] and show a more benign course with longer 
survival[38, 42] while the patients with unmutated IgVH chains genes (<2% difference from 
the germline sequence)[41] show a more aggressive disease with poorer outcome.[38, 42] 
However, according to the Swedish CLL guidelines, mutational status does not have 
influence on clinical decision-making in management of patients to the same extent as 
cytogenetics (http://www.swecll.org/Nationella-riktlinjer). 
1.1.2.4 Surrogate markers 
The sequencing of IgVH genes is costly and laborious and a number of surrogate markers 
have been introduced during the last decade.  
 
Zap-70  
Zap-70 is a protein tyrosine kinase, normally expressed by T cells and involved in T cell 
receptor (TCR) signaling. By gene array studies, it was shown to be expressed also by 
CLL cells[43-45], facilitating signaling through the B cell receptor (BCR).[46] ZAP-70 was 
reported to be one of the most differentially expressed genes between unmutated and 
mutated CLL.[44] High Zap-70 is detected in patients with unmutated IgVH and is 
associated with more aggressive disease and poor prognosis.[47-49] However, since Zap-70 
is expressed also by T cells and NK (natural killer) cells, accurate measurements must be 
made on purified leukemic B cells, and there is not yet an international standardization on 
how to measure Zap-70 in CLL.  
 
CD38 
CD38 is a 45 kDa transmembrane glycoprotein found on the surface of many immune 
cells. The expression of CD38 is easily detected by flow cytometry but the reports 
correlating CD38 expression with mutation status are inconclusive. This may be due to 
the fact that 1) CD38 expression may vary over time, 2) different cut-off levels to 
discriminate between positive and negative cases have been used, and 3) CD38 
expression show a bimodal profile in some CLL patients.[21]  
The value of CD38 as a surrogate marker for IgVH mutation status has been debated 
but CD38 is still valuable as an additional predictor of prognosis; its expression correlates 
with poor prognosis.[50] 
 
Lipoprotein lipase (LPL) 
Gene array studies identified LPL as one of the most differentially expressed genes in 
mutated versus unmutated CLL.[43-45] LPL is an enzyme that hydrolyzes lipids in 
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lipoproteins and is normally expressed in adipose tissue, cardiac and skeletal muscles, 
and lactating mammary glands. The function of LPL in CLL is not understood, but high 
LPL values correlate with worse prognosis.[51] LPL is also judged in relation to 
disintegrin and metalloproteinase 29 (ADAM29), which is overexpressed in mutated 
CLL.[45] The ratio LPL/ADAM29 is a strong prognostic indicator in CLL (high ratio 
corresponding to unmutated IgVH and bad prognosis), especially in advanced stage 
disease.[52]  
 
Telomere 
A telomere is a region of hexameric repeats at the end of each chromosome that is 
essential for chromosome integrity and stability. In normal cells the telomeres become 
shorter during each cell division and finally the length reaches a critical point at which 
cell division stops. Thus, telomere length is a measure of a cell’s proliferative history. 
The shortening of the telomeres may be counteracted by the enzyme telomerase, which is 
often upregulated in cancer.[53] In CLL, the cells from the subgroup with poor outcome 
(unmutated) have uniformly shorter telomeres and more telomerase activity than those 
from the subgroup with better outcome (mutated).[54]  
Common prognostic parameters are summarized in Table 2. 
 
Table 2. Prognostic factors in CLL (adapted from Herishanu, 2005)[55]  
Prognosticfactor Clinicalrisk 
 Low High
Patientgender Female Male
Clinicalstage BinetA
Rai0,I
BinetBorC
RaiII,III,IV
Lymphocytedoublingtime >12months <12months
IgVHgenestatus Mutated Unmutated
Geneticabnormalities None
Del13q14
Del11q22Ͳ23
Del17p13
ExpressionofCD38 Low High
ExpressionofZapͲ70 Low High
SerumlevelsofsolubleCD23 Low High
SerumlevelsofE2Ͳmicroglobulin Low High
Serumlevelsofthymidinekinase Low High
1.1.3 Treatment of CLL 
All treatment options for CLL may reduce disease progression and manage symptoms 
rather than provide curative therapy and the choice of first-line treatment is mostly 
dependent on the patient’s age, risk factors and comorbidities. For patients with no 
adverse prognostic features and/or when the disease progresses very slowly, treatment is 
put on hold as long as the patient is asymptomatic. But when a patient becomes 
symptomatic or when the disease progresses, treatment is indicated. Young patients, 
patients with high stage disease and/or adverse prognostic factors may benefit from a 
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more aggressive combination of treatment regimens.[56, 57] Most often, the first treatment 
of choice is chemotherapy with or without monoclonal antibody (mAb) therapy. 
1.1.3.1 Chemotherapy 
For many years, alkylating agents such as chlorambucil were used as the front-line 
therapy for CLL because of their low toxicity, low cost and convenience. However, the 
complete response (CR) rates were very low.[1] Combining several different alkylating 
agents (e.g. CHOP; cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin 
(vincristine), and prednisone/prednisolone) resulted in higher response rates but no 
survival benefits.[11] 
Since mid 1980s, purine analogues like fludarabine, cladribine and pentostatin, are 
the most effective agents in the treatment of CLL. Purine analogues interfere with 
ribonucleotide reductase and DNA polymerase, thereby inhibiting DNA synthesis and 
promoting apoptosis. Fludarabine as a single agent has shown much higher response 
rates, including a prolonged survival at long-term follow up, than chlorambucil.[58, 59] 
These results, however, have not been confirmed by others.[60] Combining fludarabine 
with cyclophosphamide (FC regimen) has shown improved response rates, and 
progression-free survival compared to fludarabine alone.[61] Recently, a hybrid between 
an alkylator and a purine analogue, bentamustine, was shown to be effective as first line 
therapy.[62] 
1.1.3.2 Monoclonal antibodies 
The use of mAbs in CLL treatment started a new era in the mid 1990’s. Alemtuzumab, a 
monoclonal human IgG antibody recognizing CD52, was the first antibody approved for 
CLL therapy. It is mainly used as a single agent for treatment of relapsed CLL, but also 
as first-line therapy in selected patients (e.g. 17p13 del).[63]  
Rituximab, a chimeric mAb that targets CD20, has shown limited efficacy as single-
agent treatment but the addition of rituximab to fludarabine and fludarabine plus 
cyclophosphamide (FCR regimen) has shown improved overall survival in previously 
untreated patients.[56, 57]  
Ofatumumab, another human CD20 mAb, was recently approved for usage in multi-
agent refractory CLL[64] and is currently being tested in combination with chemotherapy. 
1.1.3.3 Stem cell transplantation 
Allogeneic Stem Cell Transplantation (SCT) is the only CLL treatment capable of cure 
but is applicable only to a small number of patients. According to European Bone 
Marrow Transplant (EBMT) guidelines, reduced-dose allogeneic SCT is recommended 
for young high-risk CLL patients with poor prognostic features, in particular patients 
with tp53 abnormalities requiring therapy or patients that have relapse after autologous 
SCT.[65, 66] 
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1.1.3.4 Novel agents 
Despite advances in first-line therapy, relapse rates are high and often accompanied by 
the development of resistance towards conventional chemotherapy. Therefore, new 
agents with novel mechanisms of action are needed, especially for relapsing CLL.[67] In 
addition to new mAbs and some new chemotherapeutic agents, such as bentamustine, 
there are several novel small interfering molecules, which are currently being evaluated 
in clinical trials. These molecules may act either by inhibiting protein synthesis or block 
the action of mature proteins participating in signaling cascades important for cell cycle 
progression or angiogenesis.  
Oblimersen is an antisense oligonucleotide that targets the mRNA of the anti-
apoptotic protein Bcl-2, preventing translation of the Bcl-2 protein, thereby preventing its 
anti-apoptotic effect. Oblimersen alone has shown modest activity but in combination 
with FC regimen, the overall survival was enhanced compared to FC alone.[68] 
ABT-263 has an inhibitory effect on several members of the anti-apoptotic Bcl-2 
family and thereby induces apoptosis. ABT-263 has shown significant tumor reduction in 
a few tested CLL patients.[68]  
Obatoclax is a novel small molecule that inhibits not only Bcl-2, but also other anti-
apoptotic proteins like BCL-XL and Mcl-1. It induces apoptosis in CLL cells but showed 
side effects like neurological toxicities, somnolence, euphoria and ataxia in a phase I 
trial.[69] 
Flavopiridol inhibits the action of cyclin-dependent kinases important for cell cycle 
progression, thereby inducing cell cycle arrest. In CLL, it is believed that flavopiridol 
also induces apoptosis by down-regulation of the anti-apoptotic protein Mcl-1.[70] 
Flavopiridol has shown activity in CLL but also toxic side effects.[71] 
Vascular endothelial growth factor (VEGF) is an important inducer of angiogenesis 
and CLL cells express VEGF as well as the receptor, resulting in autocrine 
stimulation.[72] The VEGF receptor may be inhibited by either tyrosine kinase inhibitors 
(TKIs) or VEGF-blocking antibodies, leading to inhibition of the VEGF-signaling 
pathway and induction of apoptosis in CLL.([73] 
Several new mAbs are in various phases of clinical testing, targeting structures such 
as CD19, CD20, CD23, CD37, CD40, CD74 etc. Among these; TRU-016 targeting CD37 
appears to be the most promising. CD37 is expressed on B cells and transformed mature 
B cell leukemias and lymphomas but not on T cells.[74] 
1.2 PATHOPHYSIOLOGY OF CLL 
1.2.1 Origin of the CLL cell 
For a long time it was supposed that the CLL cells were small, non-dividing, immature, B 
cells that had not experienced antigens. It was also believed that defects in the apoptotic 
machinery were the reason behind the expansion of the leukemic clone. Today, CLL cells 
are considered as antigen-experienced, mature cells that escape apoptosis by the 
interaction with other cells, for example T cells and stromal cell.[75]  
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1.2.1.1 Cell proliferation and death 
In normal tissue homeostasis, there is an ongoing regulation maintaining the balance 
between cell birth and cell death. However, in cancer this balance is disrupted, which can 
be due to increased proliferation, decreased cell death, or both, resulting in cell 
accumulation of the malignant clone.[14] The accumulation of CLL cells was long 
considered to be due to defective apoptosis in combination with minimal cell 
proliferation. This idea was re-evaluated when it was discovered that 1x109 to 1x1012 
CLL cells are produced every day. Even though this is a small fraction of the entire CLL 
clone (0,1-1,75%) CLL can be considered a disease of both cell proliferation and 
defective apoptosis, where there is a homeostatic balance in patients with stable 
lymphocyte counts and an imbalance in patients with increasing lymphocyte counts.[14] 
1.2.1.2 Antigen stimulation / B cell receptor (BCR) 
The BCR is a transmembrane protein composed of a membrane Ig (mIg) homodimer 
linked to a heterodimer IgD/IgE (CD79a/CD79b).[76] (Figure 1). 
 
 
 
Figure1.Bcellreceptor.
(http://pathmicro.med.sc.edu/mayer/struͲ9.jpg)
 
 
The mIg subunit contains the antigen-binding site while the D/E subunits are responsible 
for the signal transduction into the cell interior. Ligand-binding to the BCR triggers a 
complex signaling cascade that involves a number of kinases, phosphatases and adaptor 
proteins that transmit signals resulting in cell differentiation, proliferation, survival or 
apoptosis. The BCR is considered a key molecule in CLL pathogenesis, since the clinical 
course of the disease is related to the IgVH mutational status, Zap-70 expression, the 
nature of the antigen and the strength and duration of the signal.  
CLL cells generally express low levels of the BCR.[77] The synthesis of the BCR 
components is most likely normal but the assembly on the cell surface is defective due to 
folding and glycosylation defects of the P and CD79a chains.[77, 78] However, the different 
CLL subsets exhibit differences in their capacity to signal through the BCR. CLL with 
unmutated VH genes appears to have more functional BCRs that may be stimulated by 
antigen binding and the result (proliferation or apoptosis) is determined by the balance of 
signals delivered by the activated BCR and survival signals from the microenvironment. 
CLL with mutated VH genes on the other hand, are less responsive with low capability of 
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triggering apoptosis, survival or proliferation. It is suggested that these cells may be 
either anergic, due to chronic antigen exposure, or incapable of responding to antigens 
because of BCR structure changes (e.g. posttranscriptional defects described above).[41, 79] 
When a ligand binds to the BCR, the Ig-D and Ig-E units are phosphorylated by Lyn 
and other Src kinases. Syk is recruited, activated (phosphorylated) and may 
phosphorylate several signaling intermediates that in turn activate the downstream 
signaling molecules Akt, ERK, JNK, p38MAPK, NF-AT and NF-țB which transduce 
survival and antiapoptotic signals into the nucleus (Figure 2).[80] In CLL, Lyn is strongly 
overexpressed, leading to enhanced BCR signaling, favoring CLL cell survival.[81] Also, 
prolonged activation of MEK/ERK and PI3/Akt pathways has been noted in the anti-
apoptotic signaling of the BCR in CLL.[82]  
 
 
 
Figure2.SignalingmoleculesactivateduponBCR
engagement.
ReprintedfromAutoimmunityReviews,vol7,Efremov
DG,GobessiS,LongoPG.,“Signalingpathways
activatedbyantigenͲreceptorengagementinchronic
lymphocyticleukemiaBcells”,pp:102Ͳ108,copyright
(2007),withpermissionfromElsevier.
 
 
In contrast to what was previously known, several findings suggest that CLL founder 
cells are indeed antigen-experienced. There are a number of studies supporting this 
theory. The presence of somatic hypermutations indicates that at least the mutated cases 
are antigen-stimulated (since somatic mutations occur only after antigen stimulation). But 
also the unmutated cases might be antigen-experienced since they show an obvious 
skewing in IgVH gene usage, i.e. a high proportion of CLL patients express virtually 
identical IgVH genes, indicating that they have encountered the same antigen.[83-85] Also, 
unmutated and mutated CLL have very similar gene expression profiles sharing 
similarities with antigen-experienced memory B cells.[43, 44] The nature of the promoting 
antigens is unknown, but they could be of viral or bacterial origin, or may represent 
environmental antigens or self-antigens.[75, 86] 
1.2.1.3 Genetic changes in CLL 
Gene expression profiling has revealed a number of genes that are differentially 
expressed in CLL cells compared to normal B cells.[43] However, despite years of efforts, 
no common genetic aberration among all patients has been found.[87]  
Nevertheless, some of the most common chromosomal alterations in CLL are 
affecting tumor suppressor genes; deletion 17p13 affects p53 and deletion of 11q23 
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affects ATM (ataxia telangiectasia). Both p53 and ATM play key roles in protection 
against DNA damage, cell cycle arrest and induction of apoptosis.[87] 
Other genes (NPAT, CUL5 and PPP2R1B), affecting the regulation of cell cycle and 
apoptosis have been detected in the 11q22-23 segment and have been suggested a role in 
the pathogenesis of the disease.[88] 
The most frequently deleted chromosomal region 13q14 holds 2 microRNA’s 
(miR15a and miR16-1) that negatively regulate the anti-apoptotic protein Bcl-2. Bcl-2 
repression by these microRNAs induces apoptosis and their down-regulation has been 
associated with the survival of CLL cells.[89] 
The first disease specific gene that was identified, CLLU1, is located to chromosome 
12q22 but there is no obvious difference in CLLU1 expression in patients with or without 
trisomy 12.[90] 
Certain genetic changes found in CLL have been suggested to underlie the defects in 
apoptosis. Anti-apoptotic proteins like Bcl-2, BCL-XL, BAG1 and Mcl-1 are 
overexpressed while proapoptotic proteins like BAX and BCL-XS are downregulated.[15]  
In addition to the defective apoptotic machinery of CLL, improper regulation of cell-
cycle controlling genes may also contribute to the accumulation of CLL cells. Raised 
amounts of the negative cell cycle regulator CDKN1B are detected in many CLL patients 
and may explain the arrest of CLL cells in the G0/G1 phase.[91] 
1.2.1.4 Epigenetic changes in CLL 
The current definition of epigenetics is “the study of heritable changes in gene expression 
that occur independent of changes in the primary DNA sequence”.[92] These changes are 
essential for normal development and maintenance of tissue-specific gene expression 
patterns in mammals, and are transmitted to daughter cells during mitosis. However, 
disruption of epigenetic processes can lead to altered gene function and malignant 
cellular transformation.[93] The most common epigenetic alteration in CLL is DNA 
hypermethylation.  
DNA methylation provides a stable gene silencing mechanism that plays an 
important part in regulating gene expression. Normally, a methylated gene is “turned off” 
while demethylation makes a gene “active” and available for transcription. Dysregulated 
hypo- or hypermethylation may cause upregulation of oncogenes and downregulation of 
tumor suppressor genes in various tumors.[94]  
In CLL, the overexpression of Bcl-2 is due to hypomethylation of the Bcl-2 
promotor.[95] Other genes affected by hypomethylation are the MYC oncogene[96], 
prosurvival gene Tcl-1A[97], oncogene Erb-A1[98] and human Ig light kappa constant 
genes.[93, 99] 
Gain of methylation in GC-rich promoter regions, thereby silencing tumor suppressor 
genes are described for DAPK1[100], WIF1[101], ID4[102] and SFRP1.[103] Also the 
prognostic marker Zap-70 has been found to be methylated in CLL.[104] 
One important post-translational modification is protein glycosylation, an enzyme-
directed chemical reaction where glycan structures are added to proteins and lipids. 
Glycosylation takes place in the endoplasmic reticulum (ER) and in the Golgi apparatus 
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of the cell. Glycosylation within ER is important for the proteins’ folding and stability 
while glycosylation in Golgi provides a direction “tag” to the proteins and tells them 
where to go. Glycosylation is also important for cell-cell communication and glycans are 
involved in several physiological processes such as host-pathogen interactions, cell 
differentiation, proliferation, migration.[105]  
Embryonic development as well as cellular activation is typically accompanied by 
changes in cellular glycosylation profiles and it is becoming more and more evident that 
glycosylation changes also represent a universal feature of malignant transformation and 
tumor progression.[106] It is suggested that glycosylation might be epigenetically 
regulated, creating novel biological structures without introducing deleterious changes in 
the genome.[107] 
Glycan changes in malignant cells can take a variety of forms. Examples have 
been found of loss of expression or excessive expression of certain structures, the 
persistence of incomplete or truncated structures, the accumulation of precursors and, 
less commonly, the appearance of novel structures.[106] 
1.2.2 Microenvironment 
CLL cells accumulate in vivo due to their resistance to undergo programmed cell death. 
Nevertheless, when cultured in vitro, CLL cells rapidly undergo apoptosis. This suggests 
a survival advantage provided by the microenvironment of the CLL cells. This 
microenvironment is divided in two compartments (Figure 3). As mentioned before, a 
small portion of the leukemic cells is proliferating and this takes places in the so called 
proliferation centers (PC) in the LN and BM where they interact with prolymphocytes 
and paraimmunoblasts. The majority of the CLL cell population, however, is in a resting 
phase and circulates and accumulates in the PB. This suggests a proliferating pool of cells 
in LN and BM that might feed the accumulating pool in the blood. In both PB and PC 
there are bystander cells like T cells, stromal cells, follicular dendritic cells (FDCs) and 
nurse-like cells (NLCs) that provide signals to support survival and growth. These cells 
may affect the leukemic cells by direct cell-cell interactions or by the secretion of various 
cytokines.[108, 109] T cells and stromal cells seem to be the main players and it is believed 
that activated T cells provide signals important for proliferation while stromal cells 
provide a long-term support favoring survival and accumulation of leukemic cells.[110]  
 
 
Figure3.The2compartmentmodelofCLL.
Reprintedwithpermission.©2008AmericanSociety
ofClinicalOncology.Allrightsreserved.
CaligarisͲCappioF,GhiaP,TheJournalofClinical
Oncology,vol26,2008,pp4497Ͳ4503.
 
 Chronic lymphocytic leukemia (CLL) 



12
1.2.2.1 T cells 
Despite the fact that CLL is a B cell malignancy, the number of T cells is also increased. 
This is mainly due to an increase in CD8+ T cells but the number of CD4+ T cells is also 
increased. There seems to be a small population of T cells (CD4 as well as CD8) with a 
natural and leukemia-specific response, in which they specifically recognize antigens 
expressed by tumor cells (e.g. survivin and telomerase). This population is seen more 
frequently in indolent patients. There is, however, increasing evidence that CLL T cells 
are immune-dysfunctional and this may contribute to the progress of the disease.[111, 112] 
The dysfunctional T cells show reduced CD25, CD28 and CD152 expression, proteins 
important for a normal immune response. Furthermore, the majority of CLL T cells not 
only lack anti-leukemic activity but are rather being part of the microenvironment, 
sustaining the growth of the malignant CLL clone.[113]  
Individual T cell subsets show specific tissue distribution. In the PB, there is an 
increase in regulatory T cells (particularly in advanced disease) but whether they are 
contributing to the immune-dysfunction of the T cells is not clear.[112] In the PCs on the 
other hand, there is a marked presence of CD4+ T cells, providing short-term proliferative 
support to the malignant cells.  
Many reports suggest that CD40/CD40L is the most important interaction between T 
cells and CLL cells. The CD40 receptor is a 47-50 kDa glycoprotein, a member of the 
tumor necrosis factor (TNF) receptor family. It is expressed by B cells, monocytes and 
dendritic cells (DCs). CD40L is a member of the TNF family and is expressed by 
activated CD4+ T cells, preferably in LN and BM. The CD40-CD40L interaction rescues 
CLL cells from apoptosis and induces proliferation. This is mediated by upregulation of 
cell surface molecules (CD80 and CD95), cytokine production (IL-4, TNF-D, GM-CSF), 
and chemokine production (CCL-22 and CCL-17). In addition, a subset of the leukemic 
CLL cells express both CD40 and CD40L enabling an autocrine stimulation where the 
CLL cells promote survival signals to themselves.[114]  
 
CD95/Fas  
CD95/Fas is a 40- to 50 kDa glycoprotein that belongs to the TNF receptor family and is 
expressed by T cells, B cells and NK cells. The Fas ligand (FasL) is a member of the 
TNF family and it is expressed by activated T cells. Normal Fas-FasL interaction induces 
apoptosis. However, CLL cells express little or no Fas and are thereby relatively resistant 
to Fas-mediated apoptosis. CD40 stimulation induces expression of Fas on CLL cells but 
paradoxically also provides a strong NF-țB mediated survival signal to the CLL cells.[115] 
 
CCL-22/CCL-17 
CCL22 and CCL17 are two chemokines expressed by CLL B cells from LN and BM (not 
PB). The receptor for these two chemokines, CCR4, is expressed on CD4+/CD40L+ T 
cells that upon interaction induce a strong chemokine production by the leukemic clone, 
attracting new T cells, resulting in a vicious circle, leading to CLL cell survival.[116] 
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1.2.2.2 Stromal cells 
Stromal cells are a heterogeneous population of cells, located in the BM, that are 
important in normal B cell development. These cells produce several cytokines; IL-6, IL-
7, IL-10, TGF-E, stemcellfactor B and colony-stimulating factor. However, it seems that 
the direct cell-cell contact is the most crucial event protecting the CLL cells from 
apoptosis. Several adhesion molecules are involved in the interactions between CLL cells 
and stromal cells.[117] 
A small population of these stromal cells expresses stromal cell derived factor-1 
(SDF-1), a CXC chemokine that plays an important role in B cell development. SDF-1 
binds to CXCR4, a chemokine receptor that is consistently overexpressed by CLL cells. 
The interaction between SDF-1 and CXCR4 protects CLL cells from apoptosis and 
allows their spontaneous migration beneath BM stromal cells. The latter suggests a 
mechanism for BM infiltration.[118, 119] 
Stromal cells also express vascular cell adhesion molecule-1 (VCAM-1) and inter-
cellular adhesion molecule-1 (ICAM-1). They bind to integrin receptors that are 
frequently expressed by CLL cells. VCAM-1 binds VLA-4 (D4E1 integrin) and ICAM-1 
binds LFA-1 (DLE2 integrin). The interaction between stroma cells and CLL cells via E1 
and E2 integrins protects the CLL cells from apoptosis, probably correlating with Bcl-2 
expression.[120, 121]  
CD100/Plexin-B1 is another ligand-receptor pair that seems to influence the survival 
of CLL cells. CD100 is a transmembrane protein, expressed on CLL cells. Plexin-B1 is 
expressed on BM stromal cells (as well as FDCs and activated T cells) and its binding to 
CD100 sustains the proliferation and survival of the CLL cells.[122] 
1.2.2.3 Nurse-like cells (NCLs) 
NLCs derive from CD14+ cells but have an expression profile distinct from monocytes, 
macrophages and blood-derived DCs.[123] In vitro, these cells can attract and protect CLL 
cells from apoptosis and also promote migration. It is believed that they may promote 
both CLL cell survival and BM infiltration also in vivo.[124] 
NCLs express several factors that promote interactions with the CLL cells; SDF-1, 
CD31, B cell-activating factor of the tumor necrosis factor family (BAFF) and a 
proliferation-inducing ligand (APRIL).[124, 125]  
As stromal cells, NLCs express SDF-1 and its binding to the CLL receptor CXCR4 
protects CLL cells from apoptosis and enhances BM infiltration.[2, 118, 125] 
By CD31, NLCs may bind CD38 expressed on CLL cells and this interaction 
increases cell proliferation and survival.[126] Also, it is suggested that CLL cells may 
express both CD31 and CD38, which could result in an autocrine stimulation of the 
leukemic cells.  
BAFF and APRIL are two members of the TNF family. BAFF binds to three known 
receptors, transmembrane activator and CAML interactor (TACI), B cell maturation 
antigen (BCMA) and BAFF receptor (BAFF-R or BR3). APRIL also binds to TACI and 
BCMA, but not BAFF-R. CLL cells express all three receptors. This interaction results in 
activation of NF-kB and enhanced expression of the anti-apoptotic protein Mcl-1.[124]  
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1.2.2.4 Follicular dendritic cells (FDCs) 
FDCs are accessory cells normally found in peripheral lymphoid organs but are absent in 
normal BM.[127] In CLL however, FDCs have been detected in LN as well as in BM of 
CLL patients with early BM involvement.[128] It has been suggested that FDCs provide 
proliferation and survival signals in B cell lymphoma and CLL cells cultured together 
with FDCs were rescued from apoptosis. These signals may be mediated by CD44 
interaction associated with up-regulation of the anti-apoptotic gene Mcl-1.[129]  
As stromal cells, FDCs express Plexin-B1 and the interaction with CD100 on CLL 
cells results in sustained proliferation and survival of the CLL cells.[122]  
1.2.2.5 CLL cells 
The CLL cells themselves are active players, shaping the microenvironment according to 
their needs. They secrete chemokines that attract stromal cells as well as activated T cells, 
which in turn provide signals leading to cell growth and survival.[108] The CLL cells may 
also co-express cytokines and their receptors, leading to autocrine cell growth signaling. 
Some examples are IL-2, IL-4, IL-8, TNF-D, IFN-D, IFN-J, GM-CSF, VEGF and their 
receptors.[130]  
BAFF and APRIL are a recently described survival factors for CLL cells. In addition 
to being expressed by NLCs, they are also expressed by the CLL cells that thereby 
provide survival signals to themselves.[131]  
CXCR4, CCL22 and CCL17 are chemokines expressed by CLL B cells and their 
interaction with SDF-1 on stromal cells and CCR4 on CD4+/CD40L+ T cells have been 
discussed above. 
Survivin belongs to the protein family inhibitors of apoptosis proteins (IAPs). Upon 
CD40 stimulation, survivin is expressed by CLL cells. The survivin positive cells are 
localized in the PC of LN and BM, interspersed with T cells. Survivin blocks apoptosis 
by inhibition of caspase-3 and caspase-7, terminal effectors in the apoptosis protease 
cascade. Survivin also participates in cell cycle progression and the low proliferation 
activity in CLL cells might be associated with survivin expression.[132]  
LPA (Lysophosphatidic acid) 1 is a naturally occurring soluble phospholipid that is 
expressed at higher levels in primary CLL cells as compared with normal B cells. In 
normal B cells, LPA acts as a growth factor increasing cell proliferation, intracellular 
calcium, and Ig formation. In CLL, LPA1 is suggested to be a survival factor, protecting 
the leukemic cells from apoptosis using the PI3K/Act signaling pathway.[133]  
 
Small leucine-rich proteoglycans  




15 
2 SMALL LEUCINE-RICH PROTEOGLYCANS  
2.1 INTRODUCTION 
The small leucine-rich proteoglycans (SLRPs) are a family of structurally and 
functionally related proteins that are normally present in the extracellular matrix (ECM) 
of collagen-rich tissues. The family has expanded in the last years and includes 18 genes 
divided into 5 classes; the traditionally defined classes I-III and the non-canonical classes 
IV-V (Figure 4).[134] The classification is based on number of exons encoding the gene, 
number of leucine-rich repeats (LRR), cysteine-rich regions, conservation and homology 
at the protein and genomic level, and chromosomal organization.[135] 
 
Biglycan (BGN)   chr Xq28
Decorin (DCN)    chr 12q21
Asporin (ASPN)  chr 9q22
ECM2                  chr 9q22
ECMX                  chr X
Fibromodulin (FMOD)   chr 1q32
Lumican (LUM) )           chr 12q21-22
Proline/arginine-richendleucine-richrepeat protein (PRELP) )  chr 1q32
Keratocan (KERA)         chr 12q21
Osteoadherin (OMD)     chr 9q22
Epiphyican (EPYC)     chr 12q21
Opticin (OPTC)           chr 1q32
Osteoglycin (OGN)     chr 9q22
Chondroadherin (CHAD)   chr 17q21
Nyctalopin (NYX)               chr Xp11
Tsukushi (TSKU)                chr 11q13
Podocan (PODN)                             chr 1p32
Podocan-like protein 1 (PODNL1)   chr 19p13
I
II
III
IV
V
 
Figure4.SmallleucineͲrichproteoglycan
family;classificationandchromosomal
location.
(AdaptedfromSchaeferandIozzo,2008)[136]

2.1.1 STRUCTURE AND FUNCTION 
SLRPs are small proteins (protein cores are 40-50 kDa) composed of a central domain 
containing LRRs, small cysteine clusters, ear repeats (classes I-III) and attached 
polysaccharides.[137] Some of the SLRPs may undergo proteolytic cleavage, and some 
may be tyrosine sulfated.[138, 139] The structure of the proteotype member, decorin, is 
shown in Figure 5. 
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Figure5.Schematicrepresentationofthestructuralfeaturesofdecorin.SP,signalpeptide;PP,
propeptide;Cys,cysteineͲrichregion;LRR,leucineͲrichrepeats.Theglucosaminoglycansidechainand
potentialNͲlinkedoligosaccharidesareindicatedwithsmallcircles.(AdaptedfromIozzo,1998)[138]
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The LRR region is formed by 7-20 tandem repeats of 20-29 amino acids (aa) with leucine 
(L) and asparagines (N) residues in conserved positions.[136] It can be found in most 
organisms, from bacteria to man.[140] There are more than 100 identified proteins with 
LRR domains, all are involved in protein-protein interactions.[140] The LRR region forms 
a horse-shoe, or banana-formed structure and it is thought that the ligand-binding site is 
located on the concave surface. Several SLRPs may form dimers and this is done by the 
concave surface of the molecules (Figure 6).[135, 141, 142]  
 
 
 
 
 
 
 
 
 
 
 
 
Figure6.ThehorseshoeshapeofaLRRandthedimericcoreproteinofdecorin.
ReprintedfromJournalofStructuralBiology,vol155,McEwanP,ScottP,BishopP,BellaJ,Structural
correlationsinthefamilyofsmallleucineͲrichrepeatproteinsandproteoglycans,pp294Ͳ305.
Copyright(2006),withpermissionfromElsevier.
 
The LRR region is flanked by small cysteine clusters; in most cases four cysteine 
residues in the N-terminal end and two cysteine residues in the C-terminal end, forming 
disulfide bonds.  
Most SLRPs are proteoglycans carrying one or more glucosaminoglycan (GAG) 
chains (chondroitin-, dermatan- or keratin sulfate). Others are synthesized as 
glycoproteins carrying O-linked or N-linked oligosaccharides. Some SLRPs have been 
seen with varying glycosylation suggesting different roles in different organs or 
species.[143-145]  
The ear repeat is a recently discovered distinctive feature of the SLRPs (classes I – 
III). The second last LRR is longer than the rest, typically 30 aa (classes I and III) or 31 
aa (class II) and contains a Cys residue that forms a disulfide bond with another Cys 
residue in the final LRR. The first 18–19 residues of the ear repeat seem to follow a 
conserved pattern similar to that in other LRRs. However, the latter residues are not 
highly conserved, suggesting that this part could be of functional importance, for 
example in ligand binding.[141] 
The majority of the SLRP family members map to only a few chromosomes. The 
genes encoding decorin, lumican, keratocan and epiphycan are all located on 
chromosome 12q21-23, while fibromodulin (FMOD), proline/arginine-rich end leucine-
rich repeat protein (PRELP) and opticin (OPTC) are located adjacent to each other on 
chromosome 1q32. The genes for asporin, ECM2, osteoadherin and osteoglycin are all 
found on chromosome 9q22. The clustered organization on different chromosomes 
suggests that the SLRP family has arisen from several duplication events.[146] 
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The biological role of the SLRPs is diverse. Mostly, these proteins are secreted and 
bind to membrane receptors or ECM proteins. Many SLRPs bind collagen and other 
ECM proteins, thereby regulating the structure and hydration of the ECM. Several SLRPs 
bind growth factors and their receptors, including integrins, thereby affecting cell 
proliferation and cell migration.[147] 
In addition to being secreted proteins, it is becoming evident that SLRPs may also be 
located intracellularly. An intracellular role has been proposed for decorin in binding the 
cytoskeletal protein filamin.[148] FMOD is located intracytoplasmically in basal and 
stratified keratinocytes.[149] Glypican and biglycan have been found in the nuclei of 
neurons and glioma cells.[150] For lumican, an intracellular as well as a secreted form was 
detected in lung cancer cells.[151]  
2.2 SLRPs IN CANCER 
The expression of SLRPs in cancer is becoming more and more frequently reported. 
However, the expression pattern is diverse. Decorin is upregulated in pancreatic cancer 
but downregulated in nonsmall cell lung cancer, adenocarcinoma and squamous cell 
carcinoma.[152-154] Lumican is overexpressed in a variety of malignancies, sometimes 
expressed by the tumor cells (in colorectal, cervical squamous cell carcinoma, pancreatic 
adenocarcinoma) and sometimes by fibroblasts in the ECM (breast cancer).[155-158]  
As mentioned above, changes in glycosylation are a universal feature of malignant 
transformation and tumor progression[106] and there are indeed reports about SLRPs being 
differentially glycosylated in cancer. Decorin is expressed both glycanated and non-
glycanated in laryngeal squamous cell carcinoma.[159] Lumican on the other hand is 
expressed as a nonsulphated glycoprotein in colorectal and pancreatic tumor cells while 
expressed in the proteoglycan form (with keratin sulphates) in melanoma cancer cells.[156, 
158, 160] 
Also, as mentioned above, lumican is expressed both intracellularly as well as 
secreted in lung cancer and the molecular weight of the cytoplasmic lumican differed 
from that in the culture medium owing to glycosylation of the protein.[151]  
Much more is to be learned regarding the function of SLRPs in cancer but most 
reports suggest that they may play an anti-tumor role. Decorin inhibits tumor growth[161], 
prevents metastatic spreading[162] and suppresses angiogenesis.[163] Lumican inhibits 
melanoma growth and invasion.[164]  
2.3 FIBROMODULIN, PRELP AND OPTICIN  
In 2001, a gene array study showed the enhanced expression of the SLRP FMOD in 
CLL.[43] As mentioned, FMOD is located on chromosome 1q32, adjacent to two other 
SLRP members; PRELP and OPTC.  
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2.3.1 Fibromodulin (FMOD) 
FMOD belongs to class II of the SLRP family. As the other members of class II, the 
FMOD gene comprises three exons. The protein core (43 kDa) consists of 376 aa 
supplemented with four keratin sulfate chains giving rise to a 59 kDa mature protein 
where the signal peptide of 18 aa has been removed. Twelve LRR have been defined[140] 
and in the N-terminal region, 9 tyrosine sulfation sites have been detected.[139] FMOD is 
normally expressed in cartilage, tendons and ligaments.[165] 
FMOD participates in the assembly of the ECM as it interacts with type I and type II 
collagen fibrils and inhibits fibrillogenesis in vitro.[166] It may also regulate TGF-E 
activities by sequestering TGF-E into the ECM.[167, 168]) FMOD may also participate in 
inflammation by activating complement by directly binding complement protein C1q.[169] 
FMOD expression has been detected by gene expression profiling in lung, breast, 
glioblastomas, prostate carcinomas and benign uterine tumors as leiomyomas.[170-174]  
2.3.2 Proline/arginine-rich end leucine-rich repeat protein (PRELP) 
PRELP is also a member of class II SLRPs. The PRELP gene consists of three exons. 
The primary sequence corresponds to 382 aa residues, including a signal peptide of 20 aa. 
Twelve LRR have been identified[140] as well as 4 and 2 cysteine residues in the N- and 
C-terminal parts, respectively. The N-terminal part is unusual in that it is basic and rich in 
arginine and proline residues.[175] The protein core has a molecular weight of 42 kDa and 
contains 4 potential N-linked glycosylation sites. The mature PRELP has a molecular 
weight of 55 kDa. The existence of PRELP as a proteoglycan (with GAG substitution) 
has been debated[175] but at least in human cornea and sclera, PRELP was detected with 
keratin sulfate substitution. In addition, PRELP may also bind O-linked 
oligosaccharides.[176] PRELP is normally expressed in the ECM of connective tissues, 
mainly in cartilage, lung, kidney, skin, and tendon.[175] The function of PRELP is unclear, 
but the interactions between PRELP and collagen type I and II as well as heparin and 
heparan sulphate[177] suggest that PRELP may be a molecule anchoring basement 
membranes to connective tissue.[178] PRELP has rarely been associated with diseases. In 
Hutchinson-Gilford progeria, lack of binding of collagen in basement membranes and 
cartilage suggests PRELP involvement.[179] Similar to FMOD, PRELP also interacts with 
complement proteins and may be involved in inflammation processes.[180] Also, a 
PRELP-derived peptide was shown to bind bacterial membranes and had antibacterial 
activity.[181] To our knowledge, there are no reports about PRELP in cancer.  
2.3.3 Opticin (OPTC) 
Belonging to SLRP class III, the genome of human OPTC comprises eight exons. The 
core protein (37 kDa) consists of 332 aa, the first 19 representing the signal sequence. 
Seven LRR have been identified.[140] OPTC was first described as a 45 kDa glycoprotein 
of the bovine eye[182] but has later also been detected in non-ocular tissues like cartilage, 
brain, ligament, liver, testis, muscle and skin.[182-184] 
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The OPTC protein varies in size between species; human 42–48 kDa, bovine 45 kDa 
and rat 37 kDa, probably due to differences in glycosylation and/or other post-
translational modifications. OPTC is not substituted with GAGs. Instead it is a 
glycoprotein holding a cluster of sialylated O-linked oligosaccharides in the N-terminal 
region.[182] OPTC interacts with collagen, heparin sulphate and growth hormone and may 
play a role in anchorage and growth factor reservoir.[182, 185, 186] However, the precise 
function of OPTC is still to be determined. 
Little is reported about OPTC in disease but it has been suggested a role in human 
proliferative retinal disease[187] and its downregulation is reported in neoplastic lesions of 
ciliary body epithelium.[188] It is suggested that OPTC may have anti-angiogenic 
properties by inhibiting fibroblast growth factor (FGF).[189] 
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3 RECEPTOR TYROSINE KINASES 
3.1 INTRODUCTION 
The receptor tyrosine kinases (RTKs) is a family of high-affinity membrane spanning cell 
surface receptors involved in signal transduction in all eukaryotes.[190] This family has 58 
members grouped into 20 classes based on conserved primary sequence and domain 
structure. The RTK genes are found on 19 of the 24 human chromosomes. Examples of 
well-defined RTKs are the receptors for FGF, VEGF, platelet derived growth factor 
(PDGF), hepatocyte growth factor (HGF), insulin, epidermal growth factor (EGF). For 
many of the RTKs; the ligands are known while for others, the ligands are still to be 
discovered.[191]  
The RTKs have a tyrosine kinase domain that attaches phosphate groups to tyrosine 
residues, either on themselves or on other proteins. This process called phosphorylation 
converts the target protein into an active state. Many enzymes and receptors are switched 
"on" or "off" by phosphorylation and dephosphorylation and thus, phosphorylation of 
proteins plays a significant role in a wide range of cellular processes.[192] 
3.1.1 Structure and function 
RTKs are receptors that bind growth factors, cytokines, and hormones and play important 
roles in cellular processes including proliferation, differentiation, migration, metabolism 
and survival.[190]  
Each receptor consists of an extracellular part binding the ligand, a single 
transmembrane domain and an intracellular part with a tyrosine kinase domain. The 
precise mechanism of activation and signaling differs among the receptor families[193] but 
may be generally described in a simplified version. Upon ligand-binding; the receptors 
undergo dimerization or oligomerization, bringing the intracellular tyrosine kinase 
domains in close proximity. This leads to autophosphorylation of catalytic as well as 
noncatalytic domains within the tyrosine kinase region (Figure 7).  
 
 
Figure7.Schematicstructureofreceptortyrosinekinasesandtheirmechanismofaction.
ReprintedfromCriticalReviewsinOncology/Hematology,vol50,BennasrouneAetal,Tyrosinekinasereceptors
asattractivetargetsofcancertherapy,pp23Ͳ38.Copyright(2004),withpermissionfromElsevier.
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Phosphorylation of the catalytic domain enhances the enzymatic activity of the receptor 
while phosphorylation of noncatalytic domains creates docking sites for downstream 
signaling proteins which are recruited and activated. The result is a signaling cascade and 
altered transcription of genes involved in proliferation, differentiation and migration 
(Figure 8). The most common signaling pathways for the RTKs are ras/raf/MAPK and 
PI3/Akt pathways.[193-195]  
 
 
Figure8.SchematicviewofRTKsignaling.
ReprintedfromCriticalReviewsinOncology/Hematology,vol50,BennasrouneAetal,Tyrosinekinasereceptors
asattractivetargetsofcancertherapy,pp23Ͳ38.Copyright(2004),withpermissionfromElsevier.
3.2 RTKs IN CANCER 
Many RTKs are involved in the signaling controlling cell cycle progression, cell 
proliferation, apoptosis and angiogenesis. Signaling via the receptors for EGF- and IGF 
(insulin-like growth factor) promotes cell growth and cell survival, respectively, while 
angiogenesis is initiated by signaling through VEGF, PDGF and FGF receptors.[194] In 
cancer, the receptors may be overexpressed or structurally altered due to mutations in the 
RTK genes. When the receptors are high in number, they might come in such a close 
contact that dimerization, phosphorylation and activation occurs, even without binding of 
ligand.  
Also, cancer cells may be abnormally stimulated by autocrine growth factor loops, in 
which RTKs play an important role. This leads to increased receptor signaling and 
dysregulated cell growth.[195] 
The approach to disturb the RTK signaling is a fairly novel way of disturbing growth 
advantages gained by tumor cells. Small-molecule TKIs like Gleevec (imatinib mesylate) 
as well as mAbs like cetuximab, trastuzumab, and bevacizumab are in clinical use to treat 
patients with breast cancer, colorectal cancer, chronic myelogenous leukemia (CML) and 
gastrointestinal stromal tumors.[195, 196] 
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3.3 RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS 
Receptor tyrosine kinase-like orphan receptors (RORs) belong to the RTK family and are 
involved in skeletal and neuronal development, cell movement and cell polarity. 
Vertebrates have two RORs; ROR1 and ROR2[197], which are highly homologous but are 
transcribed from different genes.[198] In addition to humans, ROR genes have been found 
in fruit flies, round worms, sea slugs, zebrafish, chicken, frogs and mice.[197] In 2001, 
gene array studies showed the elevated expression of ROR1 in CLL.[43, 44] 
3.3.1 Receptor tyrosine kinase-like orphan receptor 1 (ROR1) 
The ROR1 gene is localized at chromosome 1p31.3 (http://www.ensembl.org). The 
human ROR1 protein is 105 kDa and is composed of an extracellular region including 
one Ig domain, one cysteine-rich domain (“frizzled domain”), one kringle domain, 
followed by a transmembrane region and an intracellular region with a tyrosine kinase 
domain, a proline-rich domain straddled by two Serine/Threonine –rich domains  
(Figure 9).[197, 199] 
 
 
Ig domain
Frizzled domain
Kringle domain
Tyrosine kinase 
domain
 
Figure9.DomainstructureoftheROR1protein.
(AdaptedfromBaskar,2008).[199]
 
 
 
The ROR1 protein is highly conserved between species; mouse, human, drosophila and 
C.elegans, which verifies its importance during evolution. Ligands for ROR1 remain 
unknown but secreted proteins of the Wnt family have been proposed, since they signal 
through other cell surface receptors containing frizzled domains.[197] 
ROR1 is expressed during development in heart, lung, kidney, and to a lesser extent 
in pancreas and skeletal muscle[198], is attenuated after embryonic development, and has 
not been detected in human adult brain, kidney, heart, skeletal muscle, prostate, testis or 
ovary tissue.[199-201] ROR1 is also expressed during early stage of normal B cell 
development.[201] ROR1 has been implicated in cancer development. In human cervical 
cancer cell line HeLa, 650 known and putative kinases were silenced by siRNA 
technology, identifying 73 kinases as survival kinases (inhibiting apoptosis), of which 
ROR1 was one of the most potent.[202] ROR1 was also over-expressed in mature subsets 
of B cell acute lymphoblastic leukemia (ALL) cells.[203, 204]  
The precise ligand and signaling pathway for ROR1 is still to be determined, and 
also the function of ROR1 in CLL is unclear. It is suggested that the expression of ROR1 
in CLL is activated by the transcription factor STAT3.[205] Another report describes the 
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interaction between ROR1 and Wnt5a, leading to activation of NF-kB and enhanced CLL 
cell survival in vitro.[200] 
ROR1 is expressed in undifferentiated embryonic stem cells and has characteristics 
of an oncofetal protein (i.e. a protein typically present only during fetal development but 
found in adults with certain kinds of cancer http://en.wikipedia.org). It is expressed on 
the surface of CLL cells, is recognized and lysed by T cells, and may thereby be a 
suitable candidate for therapy.[201]  
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4 CANCER IMMUNOTHERAPY 
4.1 INTRODUCTION 
The definition of “immunotherapy” is “treatment of disease by inducing, enhancing, or 
suppressing an immune response” (www.dictionary.com). Immunotherapies designed to 
elicit or amplify an immune response, e.g. in cancer, are classified as activation 
immunotherapies whereas immunotherapies designed to reduce or suppress an existing 
immune response, as in cases of autoimmunity or allergy, are classified as suppression 
immunotherapies. 
For many years, chemotherapeutic agents and ionizing radiation have been the major 
treatment modalities in primary cancer treatments with the goal to eliminate tumor cells. 
These therapies have offered substantial benefit and some cures, but in addition to 
sometimes severe side effects, development of drug resistance leading to tumor relapses 
is a significant problem. Therefore, additional therapeutic approaches to eliminate these 
resistant tumor cells must be established.  
The concept of immunotherapy is based on the body's natural defense system and the 
main strategies for cancer immunotherapy is to provide antitumor effectors to patients 
(passive immunotherapy) and/or to stimulate the patient’s own antitumor immune 
responses (active immunotherapy).[206]  
Antigens specifically expressed by the tumors may be recognized by immune cells. 
These cells and many released signaling molecules are involved in the intriguing network 
to concur tumor cells (Figure 10). However, in many cases it seems that although the 
immune system prevents or delays tumor growth, it is eventually overwhelmed or 
evaded, and the tumor growth progresses. This is partly due to the tumors’ capacity to 
escape immune surveillance. Tumor cells develop a number of different strategies to 
avoid detection. They often lose the expression of tumor antigens or downregulate the 
MHC molecules in order to avoid detection by T cells. They may also secrete cytokines 
(e.g. VEGF, IL-10 and TGF-E that inhibit immune responses. In addition, immune 
tolerance may develop against tumor antigens, whereby the immune system no longer 
attacks the tumor cells.[207] Therefore, cancer vaccines must stimulate specific immune 
responses against the correct target. And secondly, the immune responses must be 
powerful enough to overcome the barriers that cancer cells use to protect themselves 
from attack by B cells and killer T cells.[208] 
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Figure10.Majorcellsoftheinnateandadaptiveimmunesystemsandtheirfunctionsinresponseto
atumorcell.ReprintedfromEuropeanJournalofPharmacology,vol625,BorghaeiH,SmithMR,CampbellKS,
Immunotherapyofcancer,pp41Ͳ54.Copyright(2009),withpermissionfromElsevier.
 
Historically, successful immunotherapy to treat cancer was used already in the 1890’s 
and involved the use of toxins from Streptococcus erysipelatis and Bacillus 
prodigious.[209, 210] Later, cytokine therapy using IFNJ or IL-2, became the first type of 
immunotherapy to be applied in patients with various types of cancer.[206] In more recent 
years, the use of mAbs has become standard treatment in many cancers. There are many 
ongoing clinical trials with attempt to achieve effective cancer vaccines but still, no 
therapeutic vaccine to fight cancer has yet been approved by US and European regulatory 
agencies.[211] In the last years, however, vaccines have been used in cancer prevention 
against tumor-causing hepatitis B virus[212] and papilloma virus.[213] With the increased 
knowledge of basic immune mechanisms, a wide array of immune pathways has been 
identified as attractive targets to promote anti-tumor responses in cancer patients. 
4.2 IMMUNOTHERAPY STRATEGIES 
4.2.1 Tumor antigens 
The definition of a tumor antigen is “a substance produced in tumor cells that triggers 
an immune response in the host” (http://en.wikipedia.org). Tumor antigens may 
broadly be divided into two categories: Tumor-Specific Antigens (TSAs) and Tumor-
Associated Antigens (TAAs). TSAs comprise gene products that are uniquely 
expressed in tumors while TAAs may also be expressed by other cells. However, this 
classification is somewhat risky since some antigens thought to be tumor-specific 
may be found to be expressed on some normal cells as well. Tumor antigens are 
targets of both mAbs and T cell based vaccination.  
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The ideal tumor antigen would be expressed exclusively be the tumor cells and not 
by the normal tissue (to decrease the risk of autoimmune reaction). It should also be 
detectable in all tumor cells and in the majority of patients. To give the acquired effect, it 
also needs to be essential for the survival of the tumor cells. Most tumor antigens do not 
possess these ideal characteristics and are therefore limited in their use.[214] 
4.2.2 Antibody-based immunotherapy (passive immunization) 
The earliest strategies for tumor immunotherapy relied on passive immunization, in 
which immune effectors are injected into cancer patients. MAbs can be used as carriers to 
target radioisotopes, drugs or toxins to directly kill tumor cells, but they are also used to 
stimulate components of the immune system or to interfere with signaling pathways 
within the tumor cell.[215]  
When antibodies bind to TSAs on cancer cells, a process called ADCC (antibody-
dependent cellular cytotoxicity) is activated.[216] NK cells express Fc receptors that may 
bind to the Fc portion of the bound antibody and this interaction leads to activation of the 
NK cells that release cytotoxic granules which contain proteins (perforin and granzymes) 
that kill the target cell.[217]  
Most mAbs that mediate ADCC also induce complement-dependent cytotoxicity 
(CDC). The complement system consists of a number of proteins found in blood that 
upon stimulation trigger activation of other complement proteins. The end-point of 
this cascade is the formation of pores on the tumor cell surface by proteolytic 
enzymes, leading to tumor cell lysis. Antigen-presenting cells (APCs) may then 
present tumor-derived peptides on MHC class II molecules, leading to CD4+ T cell 
activation.[217] In addition, complement activation also leads to the recruitment and 
activation of immune effector cells such as macrophages, neutrophils, basophils, mast 
cells and eosinophils, that help eliminate the tumor cells.[218]  
Antibodies can also be used to interfere with intracellular signaling pathways. 
Common targets are growth factor receptors and by blocking ligand binding and/or 
signaling through the receptor, the regulation of cell growth, apoptosis and angiogenesis 
is disturbed.[217] 
As mentioned before, tumor cells often receive survival support from the 
microenvironment and antibodies may also be used to target ECM structures, inhibiting 
processes such as angiogenesis.[217]  
4.2.3 Vaccination (active immunization)  
The purpose of tumor vaccines is to either induce immune recognition against tumor cells 
or to enhance an existing anti-tumor immune response. Successful vaccination is 
dependent upon three factors; expression and presentation of tumor antigens, host cells 
being capable of recognizing the tumor antigens, and generation of an effective immune 
response.[219] The main advantage of vaccination is the possibility to specifically target 
cancer cells without damaging normal tissues or causing debilitating side effects. 
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Single antigens or a mixture of antigens may be used as specific targets. When these 
are presented to the host, an immune response is triggered, where both T cells and B cells 
become activated and battle against the tumor cells by means of antibody production, 
cytokine production and cytotoxicity.[220] 
Numerous efforts have been made to find the most suitable way of delivering the 
vaccine to the host and to activate the most efficient immune response. WholeǦtumor cell 
vaccines utilize either tumor cells from a patient, or tumor cells from established tumor 
cell lines. In general, the major advantage of wholeǦtumor cell vaccines is that a broad 
range of TAAs are presented to the T cells, including antigens that are not yet known. 
However, whole cell vaccines might share fragments with normal cellular proteins and 
therefore involve an enhanced risk of autoimmunity compared to defined purified 
TAA’s.[221] 
DCs are considered to be the most potent APCs and, therefore, one of the most 
powerful tools for immunization. The antigen loading techniques are numerous and 
include: (1) DCs transfected with tumor-derived RNA or DNA (2) DCs loaded with 
whole tumor lysates or apoptotic tumor cells (3) DCs pulsed with tumor-derived peptides 
or whole proteins (4) DC electrofused with CLL cell (tumor-cell/DC hybrids). Other 
ways to distribute the vaccine into the host include vector-based vaccines using viral, 
bacterial or yeast gene transfer, or plasmid DNA.[222]  
Most antigens do not induce an immune response strong enough to make 
effective cancer treatment vaccines. Therefore, the vaccine is usually accompanied by 
an adjuvant; a substance that will enhance the immune response that has been set in 
motion by exposure to the antigen. There are various types of adjuvants[221] utilizing 
various mechanisms of action:  
1) Incomplete Freund’s adjuvant (IFA) helps in keeping the antigen at the injection site 
so that infiltrating APCs and effector cells can initiate a stronger immune response. 
This type of action is relevant for peptides or proteinbased vaccines that tend to 
rapidly diffuse from the site of injection. 
2) The use of aluminum-based salts has a similar function as the antigen is clumped with 
the aluminum salt.  
3) Bacterial products, such as Bacillus Calmette-Guérin (BCG) or lipopolysaccharide 
(LPS), induce strong immunostimulatory activity.  
4) Cytokines like GM-CSF, INF–D and IL-2, are commonly used as adjuvants, as they 
enhance immune responses by promoting the differentiation, activation, or recruitment 
of APCs, therefore, enhancing antigen presentation and activation of antigenǦspecific 
T cells.  
4.2.4 Adoptive T cell therapy  
In cancer patients, the number of naturally occurring tumor-specific T cells is usually 
very low. Adoptive T cell therapy is a method to drastically change the balance between 
cancer cells and immune cells. In this method, antigen-specific T cells are isolated from a 
cancer patient, activated and expanded in vitro, and re-infused into the patient. The goal 
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is a more potent anti-tumor attack, resulting in elimination of the tumor and preventing its 
recurrence.[223] 
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5 IMMUNOTHERAPY IN CLL 
5.1 GENERAL ASPECTS 
Immunotherapy of CLL includes passive antibody treatment, active immunization and 
adoptive T cell transfer. Since CLL patients suffer from impaired immune functions, the 
task of generating immune responses against the leukemic cells may be challenging, but 
even though T cell function as well as antigen presentation by DCs are impaired in 
CLL[111, 224], cytotoxic T cell responses against a number of CLL TAAs have been 
generated.[225, 226]  
5.2 IMMUNOTHERAPY STRATEGIES IN CLL 
5.2.1 Tumor antigens in CLL 
CLL cells express a number of TAAs with the potential to induce a specific anti-tumor 
response.[227] Idiotype Ig[228], Adipophilin[229], CD23[225], CD229[230], FMNL-1[231], 
MDM2[226], OFAiLRP[232], SLLP1[233], RHAMM[234], hTERT[235], survivin[236], FMOD[237] 
and ROR1[200] are some examples. The two latter were investigated in papers I and IV.  
5.2.2 Antibody therapy in CLL 
As discussed earlier (§ 1.1.3.2), the monoclonal antibodies rituximab (targeting CD20) 
and alemtuzumab (targeting CD52) have remarkably changed the treatment of CLL 
patients[238] by improving both CR rates as well as progression free survival. As most 
mAbs, rituximab and alemtuzumab act by ADCC and/or CDC.[239]  
5.2.3 Vaccination in CLL 
Theoretically, the CLL cells would be a suitable target for T cell mediated responses for 
several reasons. First, CLL arises from B cells that can act as APCs, express TAAs and 
can be targeted by allogeneic T cells. Second, since CLL is a slow-growing malignancy, 
it allows time for an immune response against the tumor cells to be generated. Third, the 
tumor cells are easily isolated as they circulate in large numbers in PB. Nevertheless, it is 
difficult to induce immune responses in CLL, mainly due to the CLL cells being 
inefficient APCs and in addition, as mentioned earlier, both CLL T cells as well as DCs 
are immune deficient.  
The numbers of vaccination clinical trials that have been performed in CLL are 
limited and due to the difficulties in finding suitable TAAs in CLL, the majority is 
performed using whole-cell vaccines.  
Two studies using 1) allogenetic DCs pulsed with tumor lysates or apoptotic 
bodies[240] and 2) autologous DCs pulsed with tumor lysates[241] reported minor clinical 
effects but without significant clinical responses.  
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Oxidized autologous tumor vaccines were evaluated in a phase I/II trial.[242] Partial 
response was noted but the response duration was short. 
A phase I study evaluating safety and immunogenicity of a vaccine consisting of 
irradiated apoptotic autologous leukemic cells, showed some immunological and minor 
clinical responses.[243] 
One recent phase I trial evaluated vaccination with a specific TAA-derived epitope. 
Apart from being “safe” the RHAMM-derived epitope R3 could to some extent elicit 
specific T cell responses against the tumor antigen RHAMM.[244]  
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6 AIMS OF THE THESIS 
Within the scope of a long-term research programme on CLL and its treatment, the 
studies underlying this thesis aimed at finding new tumor markers that might be used as 
novel targets for immunotherapy. The specific objectives were: 
 
Study 1 
To investigate the gene and protein expression of FMOD in CLL, other hematological 
malignancies and healthy controls.  
 
Study 2 
To investigate the gene and protein expression of PRELP in CLL, other hematological 
malignancies and healthy controls.  
To characterize the glycosylation pattern of PRELP in CLL cells. 
 
Study 3 
To investigate the protein expression of OPTC in CLL patients and healthy controls.  
To characterize the glycosylation pattern of OPTC in CLL cells. 
To investigate the cellular location of OPTC in CLL cells. 
 
Study 4 
To investigate the gene and protein expression of ROR1 in CLL and healthy controls. 
 
Study 5 
To investigate the result of downregulation (siRNA) of FMOD and ROR1 in CLL cells. 
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7 RESULTS  
7.1 PAPER I 
Fibromodulin, an extracellular matrix protein: characterization of its unique 
gene and protein expression in B-cell chronic lymphocytic leukemia and mantle 
cell lymphoma 
(Blood. 2005;105(12):4828-35) 
 
FMOD belongs to the family of SLRPs and is expressed in the ECM of collagen-rich 
tissues. It interacts with type I and type II collagen fibrils and inhibits fibrillogenesis in 
vitro, and may thereby participate in the assembly of the ECM. FMOD may also regulate 
TGF-E activities by sequestering TGF-E into the extracellular matrix.  
In 2001, gene expression profiling revealed FMOD as one of many genes 
overexpressed in CLL. The aim of the present study was to further investigate FMOD 
expression in CLL patients, patients with other hematological malignancies and healthy 
controls.  
FMOD was expressed at the mRNA level (RT-PCR) in all CLL patients tested 
(n=75) and in most patients with MCL (5 of 7). FMOD was not expressed in tumor cells 
of patients with T-CLL (n=5), B-PLL (n=1), T-PLL (n=1), HCL (n=10), FL (n=2), MM 
(n=4), AML (n=5), ALL (n=14) or CML (n=15). Neither was FMOD expressed in fresh 
PBMC (n=70), isolated B cells (n=6), isolated T cells (n=4), or isolated blood 
granulocytes of healthy donors (n=10). The FMOD protein was detected in the cytoplasm 
of the CLL cells (flow cytometry) and in the supernatant after in vitro cultivation 
(Western blot). Mutation analysis did not reveal any mutations in the FMOD gene of 
CLL patients (n=10). Stimulation (phorbol 12-myristate 13-acetate [PMA]/ionomycin) of 
normal B- and T lymphocytes induced weak FMOD expression, but not to the extent seen 
in freshly isolated CLL cells.  
To summarize, this study showed that FMOD is exclusively expressed in CLL and 
MCL. The unique ectopic expression in all CLL patients tested suggested that FMOD 
may play a role in the pathogenesis of the disease. Thus, this finding gave an impetus to 
further studies of the SLRP family.  
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7.2 PAPER II 
An Aberrant Unique Proline/Arginine-rich End Leucine-rich Repeat Protein 
(PRELP) is Ectopically Expressed in Chronic Lymphocytic Leukemia Cells 
(manuscript) 
 
PRELP is also a member of the SLRP family and is normally expressed in the ECM of 
connective tissue, mainly in cartilage, kidney, skin, and tendon. The function of PRELP 
is unclear, but the interactions between PRELP and collagen type I and II as well as 
heparin and heparan sulphate suggest that PRELP may be a molecule anchoring 
basement membranes to connective tissue. The PRELP gene is located in close proximity 
to the FMOD gene on chromosome 1 (1q32.1). The unexpected finding of an aberrantly 
expressed ECM protein (FMOD) raised the question whether also other SLRP family 
members might be expressed in CLL. The aim of the present study was to analyze 
PRELP in CLL cells as cluster upregulation of genes is occasionally noted in 
malignancies.  
PRELP was expressed at gene level (RT-PCR) in all CLL patients examined (n=30) 
irrespective of clinical phase (non-progressive / progressive). PRELP was also expressed 
in tumor cells of MCL patients (3/5) but not in AML (0/5), FL (0/2), T- or B-PLL (0/5), 
HCL (0/2), MM (0/6), CML (0/5), and ALL (0/10). PRELP was not expressed in fresh 
PBMC of healthy donors (0/10), enriched normal blood B cells (0/6), T cells (0/4), or 
granulocytes (0/5). PRELP was expressed in four CLL cell lines (EHEB, I83-E95, 232-
B4, WAC3-CD5) but not in cell lines derived from MM (0/1), T cell leukemia (0/1), 
ALL (0/4), AML (0/1), CML (0/1), and NK cell lymphoma (0/1). Sequencing of cDNA 
from 10 CLL patients revealed no major mutations in the PRELP gene. 
Stimulation of normal B cells, normal T cells and CLL cells (CD40L-transfected 
fibroblasts, D-CD3 mAb and PMA/ionomycin) did not induce/enhance the PRELP 
expression.  
PBMC from CLL patients were tested for PRELP protein expression in Western blot. 
A PRELP protein was detected in all CLL samples tested (n=30) but not in leukocytes of 
healthy donors (n=10). The molecular weight of the normal glycosylated PRELP protein 
was in the range 50-58 kDa. However, the PRELP expressed by CLL cells was 38 kDa. 
Molecular analysis suggests that the 38 kDa PRELP is a unique unglycosylated core 
protein, with an intact signal peptide, localized in the cytosol of the CLL cells. This 
protein was not detected in serum which, in combination with the uncleaved signal 
peptide, suggests cellular retention. An additional 76 kDa PRELP (possibly a dimer) was 
detected in a lysate fraction containing membrane and intracellular organelles. All four 
CLL lines also expressed the 38 kDa PRELP as well as the 76 kDa dimer. 
We also analyzed serum from 8 CLL patients and 8 healthy control donors by 
western blot. All serum samples showed two bands, 50 and 58 kDa, representing mature 
glycosylated PRELP, probably produced by fibroblasts in the surroundings. The 38 kDa 
and 76 kDa CLL PRELP proteins were not detected in serum from either patients or 
normal donors. 
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This is the first report connecting PRELP to cancer. An unglycosylated form of 
PRELP is expressed in CLL- and MCL-cells but not in normal white blood cells. 
Unglycosylated PRELP may be a good target for immunotherapy in that it is 
distinguishable from normal PRELP in other tissues. 
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7.3 PAPER III 
The Small Leucine-rich Proteoglycan Opticin (OPTC) is Ectopically Expressed 
and Translocated to the Nucleus of Chronic Lymphocytic Leukemia Cells 
(manuscript) 
 
As FMOD and PRELP, OPTC is also a member of the SLRP family, first identified in 
the extracellular matrix of the eye and subsequently in cartilage, brain, ligament, liver, 
testis, muscle and skin. OPTC interacts with collagen, growth hormone and heparin 
sulphate and may potentially play a role in cell anchorage, growth factor sequestration 
and regulation of angiogenesis. OPTC is located next to FMOD and PRELP on 
chromosome 1 (1q32.1). Cluster upregulation of genes is not an uncommon phenomenon 
in malignancies and the present study examining the potential expression of OPTC by 
CLL cells was performed as a logical extension to previous studies on FMOD and 
PRELP. 
This study focused on the protein expression of OPTC. Chemical deglycosylation 
was performed to determine molecular weight and glycosylation pattern while four cell 
fractionation methods were used to determine the cellular location of CLL OPTC. 
The molecular weight of the normal glycosylated OPTC protein varies between 45 
and 50 kDa. A 50 kDa OPTC protein band was detected (Western blot) in the cytosol 
from CLL cells (n=30), as well as normal leukocytes (n=10). However, the CLL cells, 
irrespective of clinical phase (non-progressive/progressive) also demonstrated a 37 kDa 
OPTC band that was not detected in healthy donors. This 37 kDa OPTC protein was 
localized in the cell nucleus and ER of the CLL cells. It was recognized both by a C-
terminal and an N-terminal antibody, indicating that it is probably not a degradation or 
cleavage product. The performed glycosylation experiments suggest that the unique 37 
kDa OPTC is an unglycosylated core protein.  
We also analyzed serum of CLL patients and healthy control donors by Western blot. 
All serum samples showed a 50 kDa band representing the mature glycosylated OPTC. 
The 37 kDa OPTC protein was not detected in sera from either group of donors. 
In addition to FMOD and PRELP, a third SLRP, OPTC, was shown for the first time 
to be expressed by CLL cells. This finding suggests that a cluster of genes are 
upregulated on chromosome 1. The unexpected localization of OPTC in the nucleus of 
CLL cells might be a useful lead in the future search for information about OPTC’s role 
in CLL.  
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7.4 PAPER IV 
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic  
lymphocytic leukemia and may serve as a putative target for therapy  
(Int J Cancer. 2008;123(5):1190-95) 
 
ROR1 belongs to the family of RTKs; transmembrane receptors involved in cellular 
processes including differentiation, proliferation, migration, angiogenesis and survival. 
ROR1 is highly conserved between species, e.g. human, mouse, drosophila and C.elegans 
and is normally expressed during development and to a lower extent in adults.  
In 2001, gene expression profiling revealed ROR1 as one of many genes 
overexpressed in CLL. The aim of the present study was to analyze gene and protein 
expression of ROR1 in CLL cells and normal blood leukocytes. 
ROR1 was detected at the mRNA level (RT-PCR) in PBMC of all CLL patients 
tested (n=100) but not in healthy donor PBMC (n=10), isolated normal B cells (n=6), 
normal T cells (n=3), or enriched blood granulocytes (n=10). Mutation analysis of cloned 
extracellular and cytoplasmic kinase domains of the ROR1 gene was performed in 10 
CLL patients and showed no major genomic aberrations.  
Protein expression was analyzed by Western blot as well as flow cytometry. ROR1 
was detected on the cell surface (PBMCs) from all CLL patients tested (n=18) but not on 
PBMC from healthy donors (n=10). The CLL cells demonstrated two different variants of 
the Ror 1 protein, 105 kDa and 130 kDa, neither of which was detected in healthy donors. 
Stimulation using PMA/ionomycin induced ROR1 expression in normal B and T 
lymphocytes, but did not enhance the fundamental ROR1 expression in CLL cells.  
FISH analysis was performed of PBMC from 3 CLL patients and showed no 
rearrangement in the chromosome 1p region. 
To summarize, this fourth study of potential targets for immunotherapy demonstrated 
that also ROR1, belonging to the RTK family, is expressed by CLL cells but not by 
normal leukocytes. The surface expression of ROR1 in all CLL patients makes it a 
promising target for future therapy.  
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7.5 PAPER V 
Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells.  
(Br J Haematol. 2010 Aug 31. [epub ahead of print]) 
 
As shown in papers I and IV, FMOD and ROR1 are two genes upregulated in CLL cells 
in contrast to normal B cells. However, the function of ROR1 and FMOD in CLL is not 
known. siRNA is today an established technique by which essentially any gene of interest 
may be knocked down, and functional effects thereof can be investigated.  
In this study, we have used siRNAs to specifically silence ROR1 and FMOD gene 
expression in CLL cells, healthy B cells and human fibroblast cell lines. 
siRNA treatment induced a significant decrease in FMOD and ROR1 both at mRNA 
(RT-PCR and realtime PCR) and protein (Western blot) levels.  
Silencing of FMOD and ROR1 resulted in statistically significant apoptosis of CLL 
cells but not of B cells from normal donors. The latter was somewhat expected since 
normal B cells do not express neither FMOD nor ROR1. However, human fibroblast cell 
lines expressing FMOD and ROR1, did not undergo apoptosis when treated with FMOD 
and ROR1 siRNA.  
This is the first report demonstrating that ROR1 and FMOD may be involved in the 
survival of CLL cells. FMOD may be relevant as a target for active immunotherapy but 
its expression in connective tissues necessitates caution due to the risk of autoimmune 
reactions. ROR1 on the other hand, is not expressed in normal tissue and may be a good 
target for therapy in CLL. 
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8 DISCUSSION 
8.1 GENERAL CONSIDERATIONS 
During the past decade, considerable progress has been achieved in the diagnosis and 
treatment of CLL. Among the new interventions various forms of immunotherapy, often 
in combination with existing therapy, are being explored in the effort to find a curative 
treatment for CLL. Passive immunization, using mAbs, has been used with favorable 
results in some cases, while the progress with active immunization has been limited. The 
main reason for the difficulties is probably the impaired immune response, inherent in the 
disease. Another problem is the adverse effects caused by autoimmune reactions. 
Finding new specific TAAs will substantially improve the possibility to target tumor 
cells without harming normal cells. The data presented in this thesis identify four new 
proteins, FMOD, PRELP, OPTC and ROR1, all expressed by CLL cells but not by 
normal white blood cells. In view of the high degree of specificity, these proteins might 
be suitable future targets for immunotherapy. 
The reason for the unexpected expression of FMOD, PRELP, OPTC and ROR1 in 
CLL is not known. Abnormalities of chromosome 1, where the four genes are located, are 
rarely seen in patients with CLL, and no mutations for either of the genes were found.  
The fact that the neighboring genes encoding FMOD, PRELP and OPTC are all 
aberrantly expressed in CLL is intriguing and might imply that this cluster of genes has a 
common gene control mechanism. Such upregulation of gene clusters has been reported 
in other malignant diseases. The possible connection in this case between gene regulation 
and pathogenesis in CLL is a topic beyond the scope of the present thesis, but further 
studies are certainly warranted.  
FMOD, PRELP and OPTC all belong to the SLRP family. There are several reports 
about other SLRPs being differentially expressed in cancer, with abnormal function as 
well as altered location compared to normal [156, 157, 159, 245] but this is the first time that 
FMOD, PRELP and OPTC have been associated with cancer. 
The results in this thesis show that FMOD, PRELP and OPTC (papers I-III) are all 
expressed in CLL with altered glycosylation (PRELP and OPTC) and abnormal location 
(OPTC). These novel findings may be of great importance in 1) understanding the 
function of these proteins in CLL and 2) the search for future treatment targets.  
ROR1 belongs to the RTK family and members of this family are occasionally 
upregulated in cancer.[246] The ROR1 protein was shown to be expressed on the surface of 
CLL cells in all patients tested but not in healthy individuals (paper IV). In contrast to 
FMOD, PRELP and OPTC, ROR1 is expressed in several other hematological 
malignancies such as MCL, marginal zone lymphoma, diffuse large B cell lymphoma and 
FL.[247] 
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8.2 FUNCTION 
The function of FMOD, PRELP, OPTC and ROR1 in CLL is still to be discovered, but 
eventually the knowledge may provide useful information in understanding the disease. 
ROR1 is normally expressed during development and is detected in undifferentiated 
embryonic stem cells.[201] Whether FMOD, PRELP and OPTC have the same 
characteristics as ROR1 is not yet known, but there are reports about proteoglycans being 
expressed during B cell development, interestingly with modulations in glycosylation 
during distinct phases of B cell differentiation.[248, 249] Perhaps FMOD, PRELP and OPTC 
are expressed during B cell development and are left in an “on-state” after tumorigenesis, 
exerting their specific, yet unknown, functions. A similar scenario could be hypothesized 
for the proteoglycan Syndecan-1 which is expressed in normal pre-B cells and in plasma 
cells as well as in CLL cells.[250] 
Unglycosylated forms of PRELP and OPTC were detected in CLL whereas ROR1 
was expressed in two forms, of which one showed higher molecular weight, possibly due 
to enhanced glycosylation. This novel finding of altered glycosylation of PRELP, OPTC 
and ROR1 in CLL needs to be further investigated. Aberrant glycosylation has been 
reported in colorectal cancer[251] thyroid cancer[252], breast cancer[253], and recently also in 
CLL.[254] There are, however, few reports about proteins being expressed in completely 
non-glycosylated forms. In Esophagus cancer, a glycoprotein called clusterin was 
reported to be expressed uncleaved and nonglycosylated in the nucleus of Esophagus 
cancer cells.[255] Another protein, Mucin 1, is overexpressed in a largely deglycosylated 
form in advanced tumors of non–small-cell lung cancer.[256] In patients with Ehlers-
Danlos syndrome, decorin is partly secreted lacking its single glycosaminoglycan side 
chain.[257] A study about proteoglycan expression in aging skin reported decorin to be 
reduced in size in mature skin compared to fetal. The small decorin was regarded as non-
glycosylated but was speculated to be a catabolic fragment of normal decorin.[258] 
Regardless of glycosylation, the core protein of several proteoglycans may act as the 
binding part responsible for interactions with other proteins. The core protein of decorin 
interacts with both collagen and fibronectin[259, 260] and may also bind TGF-ȕ and TNF-Į 
as has been shown for biglycan.[167, 261] Whether the core proteins of PRELP and OPTC 
have similar capabilities needs to be further studied. However, in vitro, ectopic 
expression of decorin protein core resulted in retarded growth and induced apoptosis of a 
variety of tumor cells. This was mediated via interaction of the decorin protein core with 
EGF receptors.[262] 
Also, the localization of OPTC in the nucleus of CLL cells needs to be further 
investigated. Interestingly, the closely related SLRP decorin was reported aberrantly 
expressed and localized to the nucleus of dysplastic oral epithelial cells. It was speculated 
by the authors that these cells had lost their ability to inhibit TGF-Į signaling and 
activation of the EGF receptor signaling pathways because of such aberrant nuclear 
localization.[245] 
Most of what is known about the normal function of FMOD, PRELP and OPTC 
concerns their interactions with ECM proteins. The microenvironment is important for 
CLL cell survival[263] and direct contact between leukemic and BM stromal cells are 
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essential to tumor cell survival.[121, 264] It is not unlikely that FMOD, PRELP and OPTC 
are involved in the communication between CLL cells and their surroundings. Thus, it is 
somewhat contradictory that PRELP and OPTC seem to be retained within the CLL cells. 
However, as mentioned previously, SLRPs may also have intracellular functions. The 
core protein of the closely related decorin has been found both in a secreted form binding 
to fibronectin[259] as well as an intracellular form binding the cytoskeletal protein 
filamin.[148] An intracellular location has even been proposed for FMOD in basal and 
stratified keratinocytes, though without any suggestion being made regarding its 
function.[149]  
In addition to their interactions with ECM proteins, FMOD, PRELP and OPTC also 
seem to interact with TGF-E[167] NF-KB[265] and retinal growth hormone[186], respectively. 
The closely related SLRP decorin interacts with EGF-R, TGF-E and p21, (a potent 
inhibitor of cell cycle progression), thereby showing cell proliferation- as well as 
apoptosis- regulatory functions.[266] The possible non-ECM interactions of FMOD, 
PRELP and OPTC need to be investigated.  
8.3 DIAGNOSIS AND PROGNOSIS 
The diagnosis of CLL is well established and is based on >5.0x109/L lymphocytes in 
peripheral blood with a characteristic phenotype; CD19+, CD5+, CD20+, CD23+, FMC7-, 
sIGweak, CD79bweak/neg. However, even though flow cytometry methods are becoming 
more and more sophisticated using multi-color systems, CLL is sometimes misdiagnosed 
as MCL, marginal zone lymphoma, B cell PLL (prolymphocytic leukemia) or 
lymphoplasmacytic lymphoma. FMOD, PRELP, and OPTC are not expressed in other 
hematological malignancies than CLL and MCL and could be a good complement to the 
markers used today.  
Our unpublished data show that the expression of ROR1 is elevated in progressive 
patients compared to indolent, suggesting ROR1 as a future prognostic marker of CLL. 
Neither FMOD, PRELP or OPTC have yet shown any potential in being a surrogate 
marker. However, more sensitive methods (e.g. real-time PCR) might detect differences 
in mRNA levels. Also, there might be differences in the degree of glycosylation that has 
not yet been discovered. More profound analyses need to be performed. 
It is known today that CLL is preceded by a condition called monoclonal B cell 
lymphocytosis (MBL). MBL is detected in a subset of the healthy population, with B 
cells immunophenotypically identical to CLL cells being present in PB.[267] Several 
studies have investigated the prevalence of MBL in the general population and the 
reported numbers varies between 0,6 and 12% depending on the detection method 
used.[268] There has been a considerable interest in the biology of MBL to better 
understand the mechanisms of CLL tumorigenesis. Although the majority of CLL cases 
appear to be preceded by MBL[269] the majority of individuals with MBL will not develop 
a hematologic malignancy. Whether or not MBL cells express FMOD, PRELP, OPTC 
and/or ROR1 needs to be investigated, but if so, the four genes might be useful tools in 
defining the MBLs that will progress into CLL.  
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8.4 TREATMENT 
Our results demonstrate that FMOD is expressed in all CLL patients but not in normal 
control PBMC, purified B or T cells (paper I). FMOD has also been shown to be 
naturally processed and presented as a TAA in primary CLL cells, enabling the 
expansion of autologous tumor-specific T cells.[237] Also, in a vaccination study where 
autologous dendritic cells were loaded with CLL cell lysate, the frequency of FMOD-
reactive T cells was enhanced.[241] These findings suggest that FMOD could be a suitable 
target for clinical vaccination trials or adoptive T cell transfer.[227, 237] However, though 
not expressed by normal blood cells, FMOD is expressed in connective tissues and the 
risk of autoimmune reactions needs to be considered. 
PRELP and OPTC are also expressed in normal connective tissue. Immunotherapy 
directed against these targets could, as for FMOD, involve a risk of autoimmune 
reactions. However, the finding of altered glycosylation of PRELP and OPTC in CLL 
(papers II and III) enhances the favorable aspects of these two proteins as possible 
vaccine targets since the glycosylation pattern distinguishes the CLL cells from normal 
cells. One possible approach would be to trigger T cells against a specific PRELP- or 
OPTC derived peptide that is unglycosylated in CLL but glycosylated in normal cells. 
ROR1 is the fourth gene found to be overexpressed in CLL (paper IV). ROR1 
belongs to the RTK family and the role of these receptors in tumor development has been 
well documented.[194, 246] Mutations in RTK genes, receptor overexpression or abnormal 
autocrine growth factor loops lead to constitutive RTK signaling, resulting in 
dysregulated cell growth and cancer.  
RTKs are multifunctional transmembrane proteins, expressed at the cell surface. 
These characteristics make them potential multisite targets that can be inhibited by 
antibodies, ligand antagonists or TKIs. The anti-ErbB2 antibody Herceptin and the TKI 
Gleevec (PDGF-R) and Iressa (EGFR) were among the first anti-RTK drugs used in the 
clinic for the therapy of patients with advanced breast cancer, CML and lung cancer, 
respectively.[195] Many have followed their paths and there are numerous ongoing clinical 
trials using mAbs or inhibitory molecules targeting RTKs both in solid tumors (as non-
small cell lung cancer, renal cell carcinoma, breast cancer, pancreatic cancer, head- and 
neck cancer, liver carcinoma) and in hematological malignancies (MM and AML) 
(http://clinicaltrials.gov). 
T cells genetically modified to express a chimeric antigen receptor specific for ROR1 
lysed primary CLL cells but not normal mature B cells in vitro.[201] T cell therapies 
targeting ROR1 may therefore be effective in CLL. However, ROR1 might also be a 
suitable target for mAb therapy as well as small molecule inhibitors. Today, mAb therapy 
in CLL includes rituxumab, targeting CD20 and alemtuzumab, targeting CD52. Although 
these mAbs have fewer side effects than standard chemotherapy, they also target normal 
cells expressing CD20 and CD52. ROR1 is not expressed by normal cells and may 
therefore give fewer side effects. In addition, ROR1 is detected at very low levels in sera 
from CLL patients[199] (which is not the case for CD52) and is therefore less likely to 
interfere with the administered mAbs. 
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FMOD, PRELP and ROR1[201] are all expressed in CLL as well as MCL (OPTC not 
yet analyzed in MCL). Both diseases are presumed to derive from mature antigen-
experienced B cells but the mechanism, timing, and role of the ectopic expression is not 
known.[270] ROR1 and FMOD may be important for the survival of CLL and MCL cells, 
as siRNA silencing of FMOD and ROR1 individually led to enhanced apoptosis of CLL 
cells (paper V). The hypothesis of ROR1 as a survival kinase was strengthened by a 
study where shRNA technology silencing of ROR1 led to induced apoptosis of Hela 
cervical carcinoma cells.[202]  
However, most reports about SLRPs in cancer describe an anti-tumor effect, 
reducing tumor growth as well as inducing apoptosis. If this would be the case for 
FMOD, PRELP and OPTC, one approach in treating CLL would be to stimulate their 
expression. Our results, however, where siRNA silencing of FMOD induced apoptosis in 
CLL cells, suggest a role for FMOD, PRELP and OPTC that would rather favor the 
survival of CLL cells. 
The traditional approach in the treatment of CLL has been to delay treatment until 
onset of symptoms. Most patients with early-stage disease continue to live for decades 
and never require treatment. However, some patients progress rapidly and will, despite 
treatment, die of the disease within 2-3 years.[68] Historical trials, which form the basis 
for the wait-and-watch approach, used single alkylating agents and yielded a CR in only 
<10% of the patients. Recent years combination treatments have achieved CR rates of up 
to 70%.[271] Patients with indolent disease show better immune responses and would 
theoretically be the ones that benefit from early immunotherapeutic intervention. The 
four novel genes investigated in this thesis are expressed in all CLL patients, irrespective 
of clinical phase (indolent/progressive). Ror expression seems to increase upon 
progression (outside the scope of this thesis). At least FMOD and ROR1, seem to be 
important for the CLL cell survival. Obviously further studies are needed, but the present 
findings imply that at least some of the newly detected tumor antigens might be suitable 
candidate targets for future immunotherapy. 
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